The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.
 
Scott Schuetze
Honoraria - EMD Serono; EMD Serono; Janssen Research & Development
Consulting or Advisory Role - EMD Serono; EMD Serono; Janssen Research & Development
Research Funding - AB Science (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Janssen Research & Development (Inst); Plexxikon (Inst); Threshold Pharmaceuticals (Inst); ZIOPHARM Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; BioMed Valley Discoveries; EMD Serono; Janssen Research & Development; Lilly
 
Shreyaskumar Patel
Consulting or Advisory Role - CytRx Corporation; Daiichi Sankyo; EMD Serono; Johnson & Johnson; Novartis
Research Funding - Eisai (Inst); Johnson & Johnson (Inst); Morphotek (Inst); PharmaMar (Inst)
 
Margaret von Mehren
Consulting or Advisory Role - Eisai; Janssen Research & Development
Research Funding - Janssen Research & Development (Inst)
 
Christopher W. Ryan
Consulting or Advisory Role - Eisai; EMD Serono; Janssen Oncology; Karyopharm Therapeutics; Onyx; Pfizer
Research Funding - Amgen (Inst); Argos Therapeutics (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Johnson & Johnson (Inst); MabVax (Inst); Morphotek (Inst); Novartis (Inst); OSI Pharmaceuticals (Inst); Pfizer (Inst); TRACON Pharma (Inst); ZIOPHARM Oncology (Inst)
 
Mohammed M. Milhem
Honoraria - Amgen; EMD Serono
Consulting or Advisory Role - Amgen; EMD Serono
Travel, Accommodations, Expenses - Amgen; EMD Serono
 
Brian Andrew Van Tine
Consulting or Advisory Role - Advaxis; Caris Life Sciences; DFINE; EMD Serono; GlaxoSmithKline; Johnson & Johnson; Lilly/ImClone; Novartis; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; DFINE; GlaxoSmithKline
Research Funding - Morphotek; Polaris
 
Sharon Anne McCarthy
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
George C. Wang
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Loreta Marquez
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Trilok V. Parekh
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Roland Elmar Knoblauch
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; Kolltan Pharmaceuticals
Consulting or Advisory Role - ARIAD; Bayer; Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Daiichi Sankyo; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Bayer (Inst); Janssen Research & Development (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Novartis (Inst)